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Deep learning neural networks are a powerful tool in the analytical toolbox of modern microscopy, but they
comewith an exacting requirement for accurately annotated, ground truth cell images. Otesteanu et al. (2021)
elegantly streamline this process, implementing network training by using patient-level rather than cell-level
disease classification.The advent of automated, high-
throughput microscopy has revolution-
ized cell biology, allowing focus on the
particular, e.g., detailed inspection of
rare cells, or providing meta-level statis-
tics of population metrics (Ljosa and Car-
penter, 2009). The incorporation of imag-
ing capability into flow cytometers has
further advanced the field (Blasi et al.,
2016), especially in application to clinical
diagnostics as hematological image anal-
ysis becomes possible (Ogle et al., 2016).
However, automated image acquisition
and quantification inevitably leads to a
requirement for automated image anal-
ysis (Caicedo et al., 2017), and this has
been provided by evermore sophisticated
machine learning approaches (Sommer
and Gerlich, 2013).
Early advances in machine learning
delivered expert systems—computer
models based on expert knowledge in
which data metrics and the rules that
linked them were user defined. Thus, in
essence, the machine simulated the
analytical steps of the human brain,
bringing much enhanced speed and reli-
ability (Buchanan and Smith, 1988). Over
time the algorithmic operations of the ma-
chine have grown increasingly complex
and opaque to the human user. This pro-
cess has led us to today’s deep learning
systems in which automated correlation,
classification, and decision making is
done within artificial neural architectures.
Thus, we have progressed from machine
learning that aimed to model the decision
making processes of the brain to systems
that mimic the brain itself. The benefit of
this computational development are
extremely powerful deep learning net-
works capable of discovering information
on processes and interactions that is hid-This is an open access arden within data patterns. The requirement
for machine supervision still remains,
however, because expert knowledge is
needed to define the labeled datasets on
which the deep learning networks are
trained. It is this aspect that Otesteanu
et al. (2021), address in their paper, pre-
senting machine learning for clinical diag-
nostics on the basis of T cell morphology
and implemented by using minimized
(weak) supervision.
The standard approach to neural
network training uses strong supervision
in which input datasets are individually
classified and labeled at the level of indi-
vidual data entries (Zhou, 2018). For
example, in cell-based diagnostics, ex-
perts have to spend a great deal of time
inspecting cell images and annotating
them according to whether they corre-
spond to a phenotype associated with a
healthy or diseased patient. This anno-
tated ‘‘ground-truth’’ dataset is then
used to train the network to automatically
recognize the designated cell types (Doan
et al., 2018) (Figure 1). This approach is
resource-heavy, requiring expert knowl-
edge, a lot of time, and accuracy in data
labeling. It also assumes a-priori knowl-
edge of what cells are important and
what they look like, but what about un-
known populations? How can we usema-
chine learning in the case of clearly indi-
cated disease, with known physiological
symptoms, but no knowledge of the
cellular biomarkers of the pathology?
Otesteanu et al. (2021) present a weak
learning approach (iCellCnn) that removes
the need for cell-level, ground truth anno-
tation by training the neural network with a
collection of cells labeled according to
patient status. They term this a ‘‘bag of
cells’’ approach, and its novelty lies inCell Reports Methods 1
ticle under the CC BY-NC-ND license (http://crthe use of patient-level classification
(Figure 1). Instead of recognizing individ-
ual cells whosemorphology indicates dis-
ease, the network is trained to recognize
distributions of image features, collected
from a population of cells. In the authors’
words they use ‘‘weak labeling of a set
of inputs, instead of a strong labeling of in-
dividual inputs.’’
The disease considered is a blood can-
cer, Sézary syndrome. This is a T cell lym-
phoma that is characterized by anoma-
lous cerebriform (brain-like) morphology
of T cell nuclei. In iCellCnn, multiple
T cell images, obtained from an individual
patient blood sample, form the input to a
convolutional autoencoder—a feature-
extracting neural network. This combines
morphological feature information from all
cells within a one-dimensional feature
vector. This vector, an abstracted
description of the blood sample, is used
as an input to a random forest classifier
which indicates the probability of the
presence of diseased cells in the input
cell collection (those of cerebriform
morphology). Thus, the training of the ma-
chine learning model defines morpholog-
ical patterns of disease at the cellular level
in a data-driven manner. As all T cells are
presented to the neural network, it learns
to ignore the non-disease-specific cells
that might confuse classification of pa-
tient status. The authors benchmark their
approach by comparing diagnoses to
those obtained by using a strong learning
approach, implemented by prior labeling
of individual cells as disease-associated
or healthy. Two levels of annotation are
adopted:
1. Naive, in which the status of the pa-
tient is assigned to all of their cells, October 25, 2021 ª 2021 The Author(s). 1
eativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Training approaches for disease diagnosis by machine learning
Shown on left, representative cells are harvested from healthy and diseased donors. The aim is to train the
artificial neural network to recognize these subsets so that it can determine the status of an undiagnosed
patient (in gray). Shown on right, feature extraction from the cell images creates the information set on
which the network bases its classifications. This might be ambiguous as some healthy cells (indicated in
orange) can present similar features to diseased cells (indicated in red). Supervised training is im-
plemented at cell level to train for recognition of diseased cells (strongly supervised), or with ‘‘bags of
cells’’ to train for recognition of a diseased patient (weakly supervised). Figure created with Biorender
(https://biorender.com/).
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patient are labeled as healthy and
vice versa for a diseased patient).
This works on an assumption that
patients with Sézary syndrome
have an increased frequency of
mutated T cell nuclei.
2. Manual, in which cells from a
healthy patient are again naively an-
notated as healthy, and 1,000
expertly identified pathological
T cells are annotated as diseased.
Although disease-associated cells
are explicitly identified, this
approach still results in morpholog-
ically abnormal T cells from healthy
individuals being labeled as
‘‘healthy,’’ so there is still the poten-
tial for distortion of the model pre-
dictions.
Although both strong and weak ap-
proaches were able to distinguish be-
tween healthy and diseased patients,
the weakly supervised training produced
the most pronounced separation of2 Cell Reports Methods 1, October 25, 2021healthy and diseased classifier scores,
estimating 14% prevalence of diseased
cells in healthy and 85% in diseased pa-
tients.
In a nice addition to the scope of the pa-
per, the authors use a custom-built micro-
fluidic system to obtain the T cell images.
This contains a 45 3 45 mm channel, in a
polydimethylsiloxane (PDMS) monomer
on a glass substrate, which elasto-inter-
tially focuses cells within the fluid stream
and can image >2,000 cells per patient.
Image capture is achieved by using a
360 objective lens and a CMOS camera.
The technical simplicity of this device
and the streamlined machine learning
analysis provide an ideal toolset for ready
adoption within clinical laboratories.
Although weakly supervised machine
learning has previously been used in
conjunction with imaging flow cytometry
to analyze blood samples (Doan et al.,
2020), this study by Otesteanu et al.
(2021) is the first to use the approach to
demonstrate disease diagnosis. Its data-
driven approach is tailor made for clinicalapplication because the medical determi-
nation of a patient’s illness becomes the
input label when training the neural
network and the output decision of the
machine. This opens the way to cell-
agnostic diagnoses where the presence
of disease can be detected but its effect
on specific morphological traits of cells
remains unknown. The black box nature
of machine learning might be seen as an
advantage in this situation given that it al-
lows clinicians to bypass the complexity
of cell morphology and its alteration by
disease, safe in the knowledge that the
accuracy of the computational decision
making has been verified by comparison
to expert medical opinion.
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